From the Journals

Targeting obesity could slow brain aging in psychosis


 

FROM THE JOURNAL OF PSYCHIATRIC RESEARCH

Being overweight or obese could be a risk factor for the kind of brain aging seen in some patients with first-episode psychosis (FEP), new research suggests.

The investigators found significant associations between BrainAGE scores and a diagnosis of FEP (P = .005), overweight/obesity category (P = .007), and body mass index (P = .02). Furthermore, the association found between BrainAGE score and BMI was related to an association between BrainAGE score and weight (P = .009), but not to height (P = .13).

“These findings raise the possibility that targeting metabolic health in FEP and intervening already at the level of overweight/obesity could slow brain aging in schizophrenia and related disorders,” reported Marian Kolenic of the National Institute of Mental Health in Klecany, Czech Republic, and his coauthors.

The researchers recruited 120 patients with FEP as defined by the ICD-10 during their first psychiatric hospitalization. People with psychotic mood disorders were excluded.

“We wanted to recruit participants at the early stages of illness, to minimize the effects of illness and medications on brain structure,” the investigators wrote.

One hundred fourteen healthy controls were recruited through advertisements, and exclusion criteria included a lifetime history of any psychiatric disorders and the presence of psychotic disorders in either first- or second-degree relatives.

All participants were asked about their medical history, including their use and/or abuse of substances. Fasting blood samples were collected on the scanning day.

Pages

Recommended Reading

Parkinson’s disease psychosis drug gets favorable review from FDA advisory panel
MDedge Neurology
Parkinson’s disease psychosis drug gets favorable review from FDA advisory panel
MDedge Neurology
APA guideline stresses judicious antipsychotics in dementia
MDedge Neurology
FDA approves first drug to treat hallucinations in Parkinson’s psychosis
MDedge Neurology
Withdrawing risperidone spikes risk for psychotic relapse in hallucinating Alzheimer’s patients
MDedge Neurology
Experts offer tips on anxiety, depression, and psychosis in Parkinson’s
MDedge Neurology
Recognizing anti-NMDA receptor encephalitis psychosis on the psych ward
MDedge Neurology
FDA approves Ingrezza for tardive dyskinesia in adults
MDedge Neurology
Austedo approved for treatment of tardive dyskinesia
MDedge Neurology
Lumateperone shows broad phase 3 potential for psychiatric disorders
MDedge Neurology